Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 19, 2020 11:13 ET | Source: Myriad Genetics, Inc.

Gemeinsamer Bundesausschuss (G-BA) fasst Beschluss zur Erstattung der Kosten des Brustkrebs-Prognosetests EndoPredict® durch die gesetzlichen Krankenkassen

NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN SALT LAKE CITY, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:...
October 16, 2020 09:05 ET | Source: Myriad Genetics, Inc.

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ SALT LAKE CITY, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader...
October 15, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

SALT LAKE CITY, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the company has filed...
September 10, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Expands Board of Directors with New Member

SALT LAKE CITY, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced...
August 21, 2020 07:05 ET | Source: Myriad Genetics, Inc.

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the American Society of...
August 14, 2020 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Inducement Awards

SALT LAKE CITY, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced...
August 13, 2020 16:08 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors

SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced...
August 13, 2020 16:07 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results

Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies Total Fourth-Quarter Revenues...
August 10, 2020 07:05 ET | Source: Myriad Genetics, Inc.

New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

SALT LAKE CITY, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a new study published in the...
August 06, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

SALT LAKE CITY, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal...